UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 544

Sortiert nach

Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma

Leukemia & lymphoma, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-9

2023

Volltextzugriff (PDF)

Metacognitive Reflection and Insight Therapy for Early Psychosis: A preliminary study of a novel integrative psychotherapy

Schizophrenia research, 2018-05, Vol.195, p.428-433

2018

Volltextzugriff (PDF)

Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders

Schizophrenia research, 2018-09, Vol.199, p.395-402

2018

Volltextzugriff (PDF)

From hepatitis C virus infection to B-cell lymphoma

Annals of oncology, 2018-01, Vol.29 (1), p.92-100

2018

Volltextzugriff (PDF)

S302: COST‐EFFECTIVENESS OF KTE‐X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

HemaSphere, 2022-06, Vol.6, p.203-204

2022

Volltextzugriff (PDF)

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi

Annals of oncology, 2014-07, Vol.25 (7), p.1404-1410

2014

Volltextzugriff (PDF)

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy

Leukemia, 2018-02, Vol.32 (2), p.353-363

2018

Volltextzugriff (PDF)

A Recovery-Oriented Approach: Application of Metacognitive Reflection and Insight Therapy (MERIT) for Youth with Clinical High Risk (CHR) for Psychosis

Behavioral sciences, 2024-04, Vol.14 (4), p.325

2024

Volltextzugriff (PDF)

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

Leukemia, 2017-03, Vol.31 (3), p.625-636

2017

Volltextzugriff (PDF)

Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium

Leukemia, 2016-02, Vol.30 (2), p.361-372

2016

Volltextzugriff (PDF)

Pelvic support, pelvic symptoms, and patient satisfaction after colpocleisis

International Urogynecology Journal, 2008-12, Vol.19 (12), p.1603-1609

2008

Volltextzugriff (PDF)

Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy

Annals of oncology, 2006-09, Vol.17 (9), p.1434-1440

2006

Volltextzugriff (PDF)

Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study

Hematological oncology, 2023-06, Vol.41 (S2), p.474-475

2023

Volltextzugriff (PDF)

Primary plasma cell leukemia: a retrospective multicenter study of 73 patients

Annals of oncology, 2011-07, Vol.22 (7), p.1628-1635

2011

Volltextzugriff (PDF)

MARGINAL ZONE LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (MZL‐IPI): A PROGNOSTIC SCORE FOR THE ENTIRE SPECTRUM OF MARGINAL ZONE LYMPHOMAS. A FIL AND SPORE‐MER STUDY

Hematological oncology, 2023-06, Vol.41 (S2), p.102-103

2023

Volltextzugriff (PDF)

TIME TO SECOND LINE BRUTON TYROSINE KINASE THERAPY AND AGE AT ITS INITIATION ARE STRONGLY ASSOCIATED WITH SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH FIRST RELAPSE OF MANTLE CELL LYMPHOMA

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31)

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

LYMFOREST‐25 : PERSONALLY‐TAILORED SURVIVAL PREDICTION OF PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA USING CLINICO‐GENOMIC PROGNOSTIC MODELS

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma

Annals of oncology, 2014-12, Vol.25 (12), p.2398-2404

2014

Volltextzugriff (PDF)

DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

PRIMARY PANCREATIC LYMPHOMA: CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND OUTCOME IN A MULTICENTRIC ITALIAN EXPERIENCE

Hematological oncology, 2019-06, Vol.37 (S2), p.455-456

2019

Volltextzugriff (PDF)

Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)

Annals of hematology, 2014-02, Vol.93 (2), p.221-231

2014

Volltextzugriff (PDF)

IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA

Hematological oncology, 2019-06, Vol.37 (S2), p.244-245

2019

Volltextzugriff (PDF)

Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma

Journal of clinical pathology, 2013-11, Vol.66 (11), p.956-961

2013

Volltextzugriff (PDF)

LENALIDOMIDE AND RITUXIMAB (ReRi) AS FRONT LINE THERAPY OF ELDERLY FRAIL PATIENTS WITH DIFFUSE LARGE B‐CELLS LYMPHOMA. FIRST PLANNED INTERIM ANALYSIS OF A PHASE II STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL)

Hematological oncology, 2019-06, Vol.37 (S2), p.427-428

2019

Volltextzugriff (PDF)

1 – 25 von 544

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(447)
Mit Volltextzugriff
(475)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma

Metacognitive Reflection and Insight Therapy for Early Psychosis: A preliminary study of a novel integrative psychotherapy

Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders

From hepatitis C virus infection to B-cell lymphoma

S302: COST‐EFFECTIVENESS OF KTE‐X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy

A Recovery-Oriented Approach: Application of Metacognitive Reflection and Insight Therapy (MERIT) for Youth with Clinical High Risk (CHR) for Psychosis

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium

Pelvic support, pelvic symptoms, and patient satisfaction after colpocleisis

Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy

Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study

Primary plasma cell leukemia: a retrospective multicenter study of 73 patients

MARGINAL ZONE LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (MZL‐IPI): A PROGNOSTIC SCORE FOR THE ENTIRE SPECTRUM OF MARGINAL ZONE LYMPHOMAS. A FIL AND SPORE‐MER STUDY

TIME TO SECOND LINE BRUTON TYROSINE KINASE THERAPY AND AGE AT ITS INITIATION ARE STRONGLY ASSOCIATED WITH SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH FIRST RELAPSE OF MANTLE CELL LYMPHOMA

PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31)

LYMFOREST‐25 : PERSONALLY‐TAILORED SURVIVAL PREDICTION OF PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA USING CLINICO‐GENOMIC PROGNOSTIC MODELS

A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma

DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI

PRIMARY PANCREATIC LYMPHOMA: CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND OUTCOME IN A MULTICENTRIC ITALIAN EXPERIENCE

Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)

IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA

Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma

LENALIDOMIDE AND RITUXIMAB (ReRi) AS FRONT LINE THERAPY OF ELDERLY FRAIL PATIENTS WITH DIFFUSE LARGE B‐CELLS LYMPHOMA. FIRST PLANNED INTERIM ANALYSIS OF A PHASE II STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL)

Suchergebnisse filtern